Federated Hermes
AMRI

Federated Hermes’s Albany Molecular Research Inc AMRI Stock Holding History

Federated Hermes’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-298
Closed -$7K – 2103
2014
Q3 		$7K Sell
298
-71
-19% -$1.45K ﹤0.01% 1796
2014
Q2 		$7K Buy
+369
New +$6.25K ﹤0.01% 1787

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Federated Hermes's AMRI Position: Q4 2014 in Review

Federated Hermes sold out of Albany Molecular Research Inc (AMRI) in Q4 2014, closing a stake of 298 shares — an estimated $7K sold.

Federated Hermes first reported a position in AMRI in Q2 2014 and held it in 2 quarters. The position peaked at $7K in Q3 2014. 132 funds tracked by Wall St. Rank hold AMRI as of Q4 2014.

  • Federated Hermes reported no remaining Albany Molecular Research Inc position as of Q4 2014 after selling out during the quarter.
  • Federated Hermes sold 298 Albany Molecular Research Inc shares in Q4 2014, an estimated $7K.
  • Federated Hermes first reported a position in Albany Molecular Research Inc in Q2 2014 and held it in 2 quarters.
  • Federated Hermes's Albany Molecular Research Inc position peaked at $7K in Q3 2014.
  • 132 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2014.

Based on Federated Hermes's 13F filing for Q4 2014, filed 10 Feb 2015.